🇺🇸 FDA
Patent

US 8710223

Protein kinase C inhibitors and uses thereof

granted A61KA61K31/506A61P

Quick answer

US patent 8710223 (Protein kinase C inhibitors and uses thereof) held by Rigel Pharmaceuticals, Inc. expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Apr 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K31/506, A61P, A61P1/00, A61P1/04